Skip to main content
Retour
UTHR logo

United Therapeutics Corporation

Qualité des données : 100%
UTHR
NASDAQ Healthcare Biotechnology
531,82 €
▲ 10,60 € (2,03%)
Cap. Boursière : 23,31B
Fourchette du Jour
517,63 € 536,02 €
Fourchette 52 Semaines
266,98 € 548,12 €
Volume
539 645
Moyenne 50J / 200J
491,10 € / 415,89 €
Clôture Précédente
521,22 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 17,5 0,4
P/B 3,3 2,9
ROE % 19,7 3,9
Net Margin % 41,9 3,8
Rev Growth 5Y % 17,2 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
579,83 € +9.0%
Low: 447,00 € High: 645,00 €
P/E Prévisionnel
17,7
BPA Prévisionnel
29,41 €
Croissance BPA (est.)
+0,0%
CA Est.
3,3 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 53,13 €
46,51 € – 59,63 €
5,8 B 4
FY2029 46,47 €
40,68 € – 52,15 €
5,1 B 4
FY2028 38,67 €
27,43 € – 51,06 €
4,3 B 10

Points Clés

Revenue grew 17,22% annually over 5 years — strong growth
ROE of 19,71% — decent returns on equity
Net margin of 41,94% shows strong profitability
Debt/Equity of 0,00 — conservative balance sheet
Generating 1,04B in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 6,61%

Croissance

Revenue Growth (5Y)
17,22%
Revenue (1Y)10,61%
Earnings (1Y)11,68%
FCF Growth (3Y)17,99%

Qualité

Return on Equity
19,71%
ROIC15,77%
Net Margin41,94%
Op. Margin46,89%

Sécurité

Debt / Equity
0,00
Current Ratio6,60
Interest Coverage76,54

Valorisation

P/E Ratio
17,46
P/B Ratio3,28
EV/EBITDA14,57
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10,61% Revenue Growth (3Y) 16,94%
Earnings Growth (1Y) 11,68% Earnings Growth (3Y) 16,42%
Revenue Growth (5Y) 17,22% Earnings Growth (5Y) 29,42%
Profitability
Revenue (TTM) 3,18B Net Income (TTM) 1,33B
ROE 19,71% ROA 16,94%
Gross Margin 87,92% Operating Margin 46,89%
Net Margin 41,94% Free Cash Flow (TTM) 1,04B
ROIC 15,77% FCF Growth (3Y) 17,99%
Safety
Debt / Equity 0,00 Current Ratio 6,60
Interest Coverage 76,54 Dividend Yield 0,00%
Valuation
P/E Ratio 17,46 P/B Ratio 3,28
P/S Ratio 7,32 PEG Ratio 1,16
EV/EBITDA 14,57 Dividend Yield 0,00%
Market Cap 23,31B Enterprise Value 21,75B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3,18B 2,88B 2,33B 1,94B 1,69B
Net Income 1,33B 1,20B 984,80M 727,30M 475,80M
EPS (Diluted) 27,86 24,64 19,81 15,00 10,06
Gross Profit 2,80B 2,57B 2,07B 1,79B 1,56B
Operating Income 1,49B 1,38B 1,18B 979,70M 555,90M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7,88B 7,36B 7,17B 6,04B 5,17B
Total Liabilities 783,80M 920,00M 1,18B 1,25B 1,21B
Shareholders' Equity 7,10B 6,44B 5,98B 4,80B 3,96B
Total Debt 0,0 300,00M 700,00M 800,00M 800,00M
Cash & Equivalents 1,56B 1,70B 1,21B 961,20M 894,80M
Current Assets 3,70B 3,87B 3,55B 3,38B 2,32B
Current Liabilities 560,60M 738,10M 804,40M 343,20M 305,40M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Balanced Risk
#105 of 151
41

Activité Récente

Entré Balanced Risk
Mar 24, 2026